Personalized nanovaccines for treating solid cancer metastases.

Area of Science:

• Oncology
• Nanotechnology
• Immunotherapy

Background:

• Cancer vaccines are explored for treating metastases, but clinical response rates are below 30%.
• Nanoparticles offer a platform to stabilize vaccines, enhance antigen recognition, and improve delivery to tumors and lymph nodes.
• Nanomedicines can potentially eradicate primary tumors and prevent or eliminate metastases.

Purpose of the Study:

• To review advanced nanocarriers for delivering cancer vaccines to metastases.
• To highlight properties of nanocarriers that improve anti-metastasis efficacy.
• To discuss combining nanovaccines with immunotherapy for metastatic cancer treatment.

Main Methods:

• Review of synthetic, semi-biogenic, and biogenic nanosystems for vaccine delivery.
• Analysis of physical and pharmacological properties influencing anti-metastasis effects.
• Examination of preclinical and clinical studies on nanovaccines and immunotherapy combinations.

Main Results:

• Nanoparticles enhance vaccine stability, antigen presentation, tumor penetration, and lymphatic drug distribution.
• Nanovaccines demonstrate potential in eradicating primary tumors and preventing/eliminating metastases.
• Combination strategies with immunotherapy target multiple steps in the metastatic cascade.

Conclusions:

• Nanocarriers represent a promising approach to improve cancer vaccine efficacy against metastases.
• Further research into nanovaccine properties and combination therapies is crucial.
• Addressing challenges in clinical translation is key for advancing cancer nanovaccines.